Elekta AB stock (SE0000163628): earnings update and oncology focus for global and US investors

Radiation-therapy specialist Elekta AB has reported new financial figures and continues to expand its cancer-care platform. What the latest numbers and strategic moves mean for the stock and for oncology technology exposure in global portfolios.

Elekta AB, a Swedish specialist in radiation therapy and radiosurgery systems for cancer treatment, remains a key name in global oncology technology. Recent company communications highlight updated financial figures and ongoing investments in software, linacs and stereotactic systems that are central to modern radiotherapy workflows, according to Elekta investor relations as of 03/20/2026 and related releases from the current fiscal year.

As of: 05/20/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Elekta
• Sector/industry: Medical technology, radiation oncology
• Headquarters/country: Stockholm, Sweden
• Core markets: Europe, North America, Asia-Pacific
• Key revenue drivers: Linear accelerators, radiosurgery systems, oncology software and service contracts
• Home exchange/listing venue: Nasdaq Stockholm (ticker: EKTA B)
• Trading currency: Swedish krona (SEK)

Elekta AB: core business model

Elekta AB focuses on solutions for radiation-based cancer care across a broad spectrum of indications. The company designs and manufactures linear accelerators and stereotactic radiosurgery systems that are used in hospitals and specialized cancer centers worldwide, according to Elekta corporate information as of 02/10/2026. In addition, Elekta offers treatment-planning and oncology information software that integrates imaging, planning and delivery.

The company’s business model combines hardware sales with a growing base of software licenses, upgrades and long-term service contracts. This mix is designed to generate upfront revenue when new systems are installed and recurring revenue through maintenance, software subscriptions and training. For many hospital customers, multi-year service agreements and software upgrades are critical to maintaining uptime and ensuring access to the latest treatment protocols and workflow improvements.

Beyond equipment and software, Elekta provides consulting, clinical training and workflow optimization services to help cancer centers deploy its technology effectively. These services support customers as they introduce new radiotherapy techniques, adapt to changing clinical standards and integrate Elekta systems with existing hospital IT infrastructures. The combination of hardware, software and services positions the company as a long-term partner in cancer care rather than a pure equipment supplier.

Main revenue and product drivers for Elekta AB

Elekta’s revenue is driven primarily by the sale and installation of linear accelerators, often referred to as linacs, which form the backbone of radiation therapy departments. These devices deliver highly controlled radiation beams to tumors while sparing surrounding tissues as much as possible. Demand for linacs is influenced by cancer incidence trends, replacement cycles for older equipment and investments in healthcare infrastructure, particularly in emerging markets, according to sector overviews cited by Reuters as of 03/21/2026.

Another important revenue driver is stereotactic radiosurgery and stereotactic body radiotherapy systems. These solutions allow for very precise, high-dose treatments in fewer sessions, which can be attractive for both patients and providers. Elekta’s portfolio in this field is aimed at neurological, spinal and certain body indications and often works in combination with advanced imaging and planning tools. The company also markets oncology information systems that can connect multiple treatment rooms, imaging devices and patient records into one coordinated software environment.

Service and maintenance contracts represent a substantial and recurring part of Elekta’s business. Hospitals typically sign multi-year agreements to cover preventive maintenance, spare parts, software updates and remote support. This recurring revenue contributes to the company’s visibility on cash flow and can partially offset the cyclicality of large capital equipment orders. For investors, this service component is an important factor when evaluating the stability of Elekta’s business compared with pure hardware-oriented medical technology providers.

Industry trends and competitive position

Radiation therapy is a central component of multidisciplinary cancer care, and global demand is influenced by demographic changes and advances in oncology. Population aging and earlier detection often increase the number of patients eligible for radiotherapy, while technological progress in imaging and planning makes high-precision treatments more accessible. Elekta operates in this environment alongside major competitors that also focus on linacs and oncology software, as described in sector analyses from Bloomberg as of 03/18/2026.

The company’s competitive position depends on its ability to innovate in hardware and software while maintaining system reliability and a strong service network. Features such as adaptive therapy, automation, and integration with imaging modalities are increasingly important differentiators in purchasing decisions. Hospitals and cancer centers often evaluate not only price and hardware specifications but also how well a system fits into existing IT architectures, regulatory requirements and reimbursement models in each region.

Regulatory approvals and clinical evidence also play a role in adoption patterns across markets. For example, when a new treatment protocol or technology receives clearance from regulatory bodies and supportive data from clinical studies, hospitals may be more willing to invest in corresponding equipment and software. As a result, Elekta’s research collaborations with academic centers and hospital networks can be strategically important over the long term, even though they may not translate into immediate revenue.

Why Elekta AB matters for US investors

Although Elekta is headquartered in Sweden and its primary listing is on Nasdaq Stockholm, its technology is widely used in North America, including the United States. The US is a key market for advanced radiation therapy equipment and software because of the high volume of cancer cases, the relatively broad availability of radiotherapy infrastructure and the focus on cutting-edge treatment techniques, according to oncology market reviews referenced by S&P Global Market Intelligence as of 03/25/2026.

For US-based investors, Elekta represents exposure to global oncology technology through a European-listed medical technology group. This can diversify sector allocations beyond domestic names while still connecting to themes such as precision medicine, hospital capital spending and healthcare digitalization. Because the shares trade in Swedish krona, currency movements between the US dollar and the Swedish krona can also influence the performance of any position when viewed from a US-dollar perspective.

In addition, Elekta’s installed base and service contracts in the US create recurring revenue streams that are linked to the ongoing operation of cancer centers rather than one-off sales. For investors who track healthcare equipment cycles and hospital budgets in the United States, developments in reimbursement policies, capital spending and oncology program expansion can be relevant to Elekta’s demand environment, even though the stock itself is traded on a European exchange.

What type of investor might consider Elekta AB – and who should be cautious?

Elekta may be of interest to investors who follow global medical technology and oncology trends and who are comfortable with European listings and foreign-exchange exposure. The company’s focus on radiation therapy equipment and oncology software means that its fortunes are closely tied to hospital investment cycles, cancer treatment protocols and regulatory frameworks in multiple regions. These factors can lead to periods of strong order growth but also phases of slower capital spending.

More cautious investors may focus on the potential risks associated with large, project-based orders, as delays in tender processes or installation schedules can affect quarterly revenue patterns. In addition, competition from other radiation therapy and oncology software providers may influence pricing and margins. For investors with lower risk tolerance, these dynamics, combined with currency volatility for non-Swedish holders, could be important considerations when evaluating any exposure to the stock.

Overall, Elekta’s profile tends to align with investors who accept moderate to higher volatility in exchange for exposure to long-term structural trends in cancer care technology. Those with a shorter investment horizon or a preference for purely domestic US securities may find the combination of sector-specific and currency-related fluctuations less suitable for their portfolio objectives.

Conclusion

Elekta AB is positioned as a specialized provider of radiation therapy systems, radiosurgery solutions and oncology software with a global customer base. The company’s business model blends capital equipment installations with recurring revenue from service contracts and software, which can support longer-term visibility in a sector shaped by demographic trends and technological innovation. For US investors, the stock offers exposure to oncology technology beyond domestic markets but also introduces European listing and currency factors. Whether Elekta fits into a particular portfolio depends on individual objectives, risk tolerance, and the role that medical technology and international diversification play in an overall investment strategy.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.